Company Description
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC sti...
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Valuation
Price to Sales Ratio
17.08
Price to Book Ratio
1.55
Enterprise Value to EBITDA
0.53
Enterprise Value to Sales
-15.44
Efficiency
Total Asset Turnover
0.05
Liquidity
Current Ratio
5.00
Quick Ratio
5.00
Cash Ratio
4.87
Profitability
Gross Margin
88.03
Operating Margin
-1,159.67
Pretax Margin
-1,310.17
Net Margin
-1,310.17
Return on Assets
-59.12
Return on Equity
-95.87
Return on Total Capital
-59.57
Capital Structure
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Peter M. Hecht | 57 | 2019 | Chief Executive Officer & Director |
Ms. Cheryl Gault | 41 | - | Head-Strategy |
Ms. Anjeza Gjino | 37 | 2019 | Secretary & Vice President-Finance |
Mr. Kevin Durfee | - | - | Vice President-Information Technology & Facilities |
Dr. G. Todd Milne | - | - | Vice President-Corporate Development |
Insider Actions
06/03/2021 |
Peter M. Hecht Chief Executive Officer; Director |
823,170 | Acquisition at $3.28 per share. | 2,699,997 |
06/03/2021 |
Polaris Growth Management LLC Director |
3,322 | Acquisition at $3.12 per share. | 10,364 |
06/03/2021 |
Polaris Growth Management LLC Director |
92,831 | Acquisition at $3.12 per share. | 289,632 |
06/03/2021 |
Slate Path Capital LP |
961,538 | Acquisition at $3.12 per share. | 2,999,998 |
05/06/2021 |
Peter M. Hecht Chief Executive Officer; Director |
302,000 | Acquisition at $2.43 per share. | 733,860 |
05/05/2021 |
Peter M. Hecht Chief Executive Officer; Director |
398,001 | Acquisition at $2.53 per share. | 1,006,942 |
05/04/2021 |
Peter M. Hecht Chief Executive Officer; Director |
300,000 | Acquisition at $2.29 per share. | 687,000 |
02/25/2021 |
Anjeza Gjino Chief Financial Officer |
1,824 | Disposition at $4 per share. | 7,296 |
02/25/2021 |
Christopher I. Wright Chief Medical Officer |
2,637 | Disposition at $3.99 per share. | 10,521 |
12/28/2020 |
Mark G. Currie President and CSO |
20,107 | Disposition at $3.01 per share. | 60,522 |
11/09/2020 |
Andreas Eugen Busch Chief Innovation Officer |
125,000 | Acquisition at $2.53 per share. | 316,250 |
11/06/2020 |
William I. Huyett Chief Financial Officer |
3,827 | Disposition at $2.52 per share. | 9,644 |
02/21/2020 |
William I. Huyett Chief Financial Officer |
3,559 | Disposition at $5.12 per share. | 18,222 |
12/30/2019 |
Mark G. Currie President and CSO |
25,000 | Disposition at $2.48 per share. | 62,000 |
MarketWatch News on CYCN
-
Cyclerion Therapeutics started at buy with $14 stock price target at Truist
- Tomi Kilgore
Other News on CYCN
-
10-Q: CYCLERION THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Cyclerion posts topline data for mitochondrial disease candidate
- Seeking Alpha
-
Cyclerion Therapeutics reports Q1 results
- Seeking Alpha
-
10-K: CYCLERION THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Warning: CYCN is at high risk of performing badly
- Seeking Alpha
-
Warning: CYCN is at high risk of performing badly
- Seeking Alpha
-
ME, CYCN and FWBI among pre market gainers
- Seeking Alpha
-
DPW, ANVS and CFMS among pre market gainers
- Seeking Alpha
-
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- InvestorPlace.com
- Loading more headlines...